Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;149(12):10965-10974.
doi: 10.1007/s00432-023-04973-y. Epub 2023 Jun 17.

One-week external beam partial breast irradiation: survival and toxicity outcomes

Riccardo Ray Colciago  1   2 , Eliana La Rocca  3 , Carlotta Giandini  2 , Alicia Rejas Mateo  4 , Nice Bedini  2 , Giuseppe Capri  5 , Secondo Folli  6 , Laura Lozza  2 , Silvia Meroni  7 , Pignoli Emanuele  7 , Tiziana Rancati  8 , Stefano Arcangeli  1   9 , Maria Carmen De Santis  2
Affiliations

One-week external beam partial breast irradiation: survival and toxicity outcomes

Riccardo Ray Colciago et al. J Cancer Res Clin Oncol. 2023 Sep.

Abstract

Purpose: According to ASTRO and ESTRO guidelines, external beam Partial Breast Irradiation (PBI) is a valid option for early-stage breast cancer patients. Nevertheless, there is lack of consensus about the best treatment schedule.

Methods: We retrospectively analysed data of female patients treated at our institution from 2013 to 2022 with adjuvant "one-week" partial breast irradiation. Clinical Target Volume (CTV) was an isotropic expansion of 15 mm from the tumour bed (identified as the breast tissue between surgical clips). The treatment schedule was 30 Gy delivered with Volumetric Modulated Arc Therapy in 5 daily fractions. The primary endpoint was Local Control (LC). Disease-Free Survival (DFS), Overall Survival (OS) and safety were secondary endpoints.

Results: Three hundred and forty-four patients with a median age of 69 (33-87) years were included in the study. After a median follow-up of 34 (7-105) months, 7 patients (2.0%) developed a local recurrence. Three-year LC, DFS and OS actuarial rates were 97.5% (95% CI 96.2%-98.8%), 95.7% (95% CI 94.2%-97.2%), and 96.9% (95% CI 95.7%-98.1%), respectively. Ten (2.9%) patients experienced grade 2 late toxicities. Five (1.5%) patients reported late cardiac major events. Three (0.9%) late pulmonary toxicities were detected. One hundred and five (30.5%) patients reported fat necrosis. Good or excellent cosmetic evaluation following the Harvard Scale was reported in 252 (96.9%) cases by the physicians, while in 241 (89.2%) cases by the patients.

Conclusion: "One-week" PBI is effective and safe, and this schedule is a valid option for highly selected early breast cancer patients.

Keywords: Breast cancer; Feasibility; Partial breast irradiation; Radiation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

This study was not funded. The authors declare that they have no conflicts of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was approved by the local ethical committee, with the registration number: INT 110/22. Informed consent was obtained from all individual participants involved in the study.

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival and toxicity curves
Fig. 2
Fig. 2
Cosmesis outcomes
See this image and copyright information in PMC

References

    1. Belkacemi Y, Hanna NE, Besnard C, Majdoul S, Gligorov J (2018) Local and regional breast cancer recurrences: salvage therapy options in the new era of molecular subtypes. Front Oncol 17(8):112. 10.3389/fonc.2018.00112 - PMC - PubMed
    1. Bourgier C, Pichenot C, Verstraet R, El Nemr M, Heymann S, Biron B, Delaloge S, Mathieu MC, Garbay JR, Bourhis J, Taghian AG, Marsiglia H (2011) Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial). Int J Radiat Oncol Biol Phys 81(5):1228–1235. 10.1016/j.ijrobp.2010.07.040 - PubMed
    1. Buchholz TA, Ali S, Hunt KK (2020) Multidisciplinary management of locoregional recurrent breast cancer. J Clin Oncol 38(20):2321–2328. 10.1200/JCO.19.02806 - PMC - PubMed
    1. Ciabattoni A, Gregucci F, De Rose F et al (2022) AIRO breast cancer group best clinical practice 2022 update. Tumori J 108(2_suppl):1–144. 10.1177/03008916221088885 - PubMed
    1. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390(10099):1048–1060. 10.1016/S0140-6736(17)31145-5 - PMC - PubMed

LinkOut - more resources